Ameriprise Financial Inc. Decreases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Ameriprise Financial Inc. cut its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 78.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 70,427 shares of the biotechnology company's stock after selling 257,884 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.33% of Enanta Pharmaceuticals worth $405,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. AlphaQuest LLC grew its stake in shares of Enanta Pharmaceuticals by 16.4% during the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 3,137 shares during the period. Thrivent Financial for Lutherans bought a new position in Enanta Pharmaceuticals in the 4th quarter worth approximately $254,000. Marshall Wace LLP boosted its stake in Enanta Pharmaceuticals by 9.3% in the 4th quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock worth $5,348,000 after purchasing an additional 79,197 shares during the period. Norges Bank bought a new position in Enanta Pharmaceuticals in the 4th quarter worth approximately $234,000. Finally, Invesco Ltd. boosted its stake in Enanta Pharmaceuticals by 7.3% in the 4th quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company's stock worth $268,000 after purchasing an additional 3,186 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ENTA has been the subject of several recent analyst reports. Wall Street Zen upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th. JMP Securities upped their price target on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the stock a "market outperform" rating in a research note on Tuesday, June 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ ENTA traded up $0.26 during midday trading on Friday, reaching $7.47. 118,893 shares of the stock traded hands, compared to its average volume of 283,923. The stock has a market capitalization of $159.69 million, a PE ratio of -1.51 and a beta of 0.76. Enanta Pharmaceuticals, Inc. has a one year low of $4.09 and a one year high of $17.24. The company's 50 day moving average is $5.53 and its 200 day moving average is $6.18.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.02). The firm had revenue of $14.93 million for the quarter, compared to the consensus estimate of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.